A Review on Targeted Drug Development for Breast Cancer Using Innovative Active Pharmaceutical Ingredients (APIs)

Abstract

Aim: This study reviews the recent trends in targeted drug development against breast cancer using innovative active pharmaceutical ingredients (APIs) to achieve better therapeutic outcomes. Study Design: A review of literature from 2019 to 2024, exploring active pharmaceutical ingredients being used in breast cancer treatment, focusing on nanotechnology, molecular targeting, and personalized medicine approaches. Methodology: Extensive review of the literature on peer-reviewed articles was done from Google Scholar, PubMed, Scopus, and Cochrane Library. Inclusion criteria included studies discussing innovative active pharmaceutical ingredients, subtypes of breast cancer, and targeted therapy clinical applications. Results: A total of 12 key studies were identified from the review that emphasized the transformative potential of APIs in the treatment of breast cancer including HER2-enriched, Luminal A, Luminal B, and Basal-like. Notable innovations in APIs include trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) targeting HER2-positive breast cancer; polymeric micelles for co-delivery of paclitaxel and siRNA, which showed synergistic tumor growth inhibition in vivo; and gold nanoparticles conjugated with folic acid, improving targeted drug delivery. Moreover, personalized medicine approaches, such as next-generation sequencing for identifying actionable mutations and companion diagnostics for patient-specific therapy, showed considerable enhancement in therapeutic efficacy. Conclusion: Innovative APIs are one of the most promising frontiers in the treatment of breast cancer, which overcomes the drawbacks of traditional treatments. However, challenges remain in the standardization, regulatory approval, and global accessibility of these treatments. The findings indicate that advanced technologies must be combined with regulatory frameworks to achieve sustainable advancement in oncology therapeutics.